News | August 18, 2014

Clinical Study Uses Hyperthermia, Proton Therapy to Treat Patients With Soft Tissue Sarcoma

August 18, 2014 — BSD Medical Corp. reported initiation of a Phase I/II study (HYPROSAR) using hyperthermia, delivered using either the BSD-2000 Hyperthermia System (BSD-2000) or the BSD-500 Hyperthermia System (BSD-500), combined with proton radiotherapy to treat patients with unresectable soft tissue sarcoma. The clinical study has been designed in joint cooperation with Kantonsspital Aarau, Paul Scherrer Institute, Villigen, Uniklinik Balgrist, Zurich, and University Hospital, Zurich. The Phase I/II study will include 28 adult patients with primary and unresectable soft tissue sarcomas of extremities and trunk (excluding abdominal tumors). The trial has been registered at ClinicalTrials.gov (NCT01904565) and is open for patient enrollment.

The researchers announced the study initiation at the European Society for Hyperthermic Oncology (ESHO) Annual Conference. Dr. N.R. Datta presented the basis for the study, "Thermoradiobiological basis of ''HYPROSAR'': A clinical trial with hyperthermia and proton radiotherapy in unresectable soft tissue sarcoma." During the presentation, Datta stated that studies have demonstrated that hyperthermia increases the efficacy of radiation with minimal morbidity, is especially cytotoxic for large bulky tumors, and prevents the repair of radiation induced DNA damage. He also reported that proton beam radiotherapy has superior physical dose distribution profiles, as compared to conventional radiotherapy. Datta concluded, "Consequently, for unresectable primary and recurrent soft tissue sarcomas, the thermoradiobiological and physical advantages of hyperthermia and proton beam radiotherapy could be expected to produce a greater tumour regression, higher tumour downstaging, superior resectability with organ and limb preservation and improved survival outcome without significant treatment related morbidity."

For more information: www.BSDMedical.com

Related Content

Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer
News | Proton Therapy | May 31, 2018
Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at...
More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage
News | Proton Therapy | May 25, 2018
The Alliance for Proton Therapy Access has released a national report revealing the heavy emotional and financial...
MedStar Georgetown Conducts World's First Hyperscan Proton Therapy Treatment
News | Proton Therapy | April 27, 2018
For the first time, cancer patients in the Washington, D.C. metropolitan region have access to proton therapy, now...
First Patient Treated on Mevion's S250i Proton Therapy System
News | Proton Therapy | April 05, 2018
Mevion Medical Systems announced the treatment of the first patient in the world on the Mevion S250i Proton Therapy...
MEDraysintell released a report in January revising its projection for the number of proton therapy centers worldwide by 2030 down from 1,200 to 900. The company said that more than 50 proton therapy treatment rooms would need to be opened every year from 2018 to 2030 to hit the original projection of 1,200.

MEDraysintell released a report in January revising its projection for the number of proton therapy centers worldwide by 2030 down from 1,200 to 900. The company said that more than 50 proton therapy treatment rooms would need to be opened every year from 2018 to 2030 to hit the original projection of 1,200.

Feature | Proton Therapy | March 06, 2018 | By Jeff Zagoudis
Proton therapy has experienced major growth in the last decade, but that growth seems to have slowed slightly in recent...
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
RayStation Selected for India’s First Proton Center
News | Proton Therapy | February 01, 2018
February 1, 2018 – Apollo Hospitals, Asia´s foremost integrated healthcare provider, has selected RayStation for a ne
IBA Announces First Patient Treated with Proteus PLUS in The Netherlands
News | Proton Therapy | January 25, 2018
January 25, 2018 –  IBA (Ion Beam Applications SA) has announced that the University Medical Center Groningen (UMCG)
Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
Overlay Init